菜单
Recommends applying standard acromegaly treatment approaches to normalize GH and IGF-1 in patients with pituitary gigantism. Use when evaluating a child or adolescent with excessive linear growth prior to epiphyseal closure, elevated IGF-1, and nonsuppressed GH after glucose load.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-gigantism-standard-approaches命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
基于 SOC 职业分类
正在显示 SKILL.md
| name | endo-gigantism-standard-approaches |
| description | Recommends applying standard acromegaly treatment approaches to normalize GH and IGF-1 in patients with pituitary gigantism. Use when evaluating a child or adolescent with excessive linear growth prior to epiphyseal closure, elevated IGF-1, and nonsuppressed GH after glucose load. |
Collect clinical history (growth velocity, pubertal stage), physical exam (acral enlargement, facial changes), labs (age‑adjusted serum IGF‑1, GH suppression after 75 g oral glucose tolerance test), and pituitary MRI with contrast to assess tumor size, cavernous sinus invasion, and chiasmal proximity.
If IGF‑1 exceeds the age‑adjusted upper limit and GH fails to suppress to <0.4 µg/L after OGTT, with MRI confirming a GH‑secreting adenoma → rule in gigantism; otherwise rule out and consider alternative causes of overgrowth (e.g., genetic syndromes, precocious puberty).
Stratify by surgical resectability: tumor confined to sella with minimal cavernous sinus invasion → primary transsphenoidal surgery; extensive cavernous sinus invasion or chiasmal compression making gross total resection unlikely → primary medical therapy.
For resectable tumors, perform transsphenoidal surgery; for unresectable disease or as adjuvant post‑surgery, initiate medical therapy (first‑line somatostatin receptor ligand, add pegvisomant if inadequate, consider dopamine agonist for mild IGF‑1 elevation) targeting age‑adjusted IGF‑1 normalization and random GH <1 µg/L.
Do not rely on random GH alone for diagnosis; avoid long‑acting SRLs or pegvisomant in pregnancy without specialist input; do not delay surgery in rapidly progressive cases due to irreversible skeletal overgrowth; use age‑adjusted IGF‑1 norms; avoid radiotherapy as first‑line in children because of neurocognitive risk.
A 14‑year‑old presents with 10 cm/year growth, coarse facial features, and enlarged hands. IGF‑1 is 2× the upper limit for age, GH 2 µg/L after OGTT. MRI shows a 12 mm pituitary macroadenoma touching the cavernous sinus. Transsphenoidal surgery reduces tumor size but IGF‑1 remains elevated; monthly lanreotide 120 mg normalizes IGF‑1 at 6 months.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700